MyMD Pharmaceuticals Names Mitchell Glass M.D. as President and Chief Medical Officer

MyMD Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for age-related diseases and autoimmune and inflammatory conditions, has announced significant changes in its leadership team. The company appointed Mitchell Glass, M.D., a current board member, as its new president and chief medical officer (CMO). Additionally, Stephen Friscia, an experienced investment strategist, has been named as an independent board member.

Dr. Mitchell Glass brings to MyMD Pharmaceuticals a 35-year career in the life sciences sector, boasting multiple drug approvals such as Accolate®, Avandia®, and Coreg®. He has extensive experience in guiding companies through regulatory strategies, including the submission of five New Drug Applications (NDAs) and Marketing Authorization Applications (MAAs), participation in seven pre-NDA meetings, twelve End of Phase 2 (EOP2) meetings, and over 80 Investigational New Drug (IND) applications. His expertise in internal medicine, pulmonary and critical care medicine, particularly in inflammatory diseases and immunopathology, is expected to be instrumental as MyMD progresses with its clinical development.

Josh Silverman, chairman of the board at MyMD, expressed confidence in Dr. Glass's ability to steer the company through its mid-stage clinical trials, especially following the successful and statistically significant Phase 2 study of MYMD-1® in sarcopenia/frailty completed last year. Dr. Glass has a proven track record of successfully managing early- to mid-stage clinical development and regulatory strategies, making him a valuable asset to MyMD Pharmaceuticals.

Dr. Glass shared his enthusiasm for joining MyMD at a pivotal moment, emphasizing that the company's initial Phase 2 data would guide larger studies of MYMD-1 focused on patient outcomes. He looks forward to providing updates on the progress of their novel TNF-α inhibitor, which forms a critical part of MyMD's therapeutic platforms.

MyMD's other significant appointment, Stephen Friscia, brings two decades of equity research and portfolio management experience to the board. He is the manager and co-founder of Kipps Capital, a family office established in 2016. Friscia's previous roles include managing director and portfolio manager positions at several institutional investment and asset management firms, where he focused on small and mid-cap value equities. Josh Silverman highlighted that Friscia’s expertise in the healthcare sector would be vital as the company moves forward with its strategic initiatives.

MyMD Pharmaceuticals is engaged in developing two novel therapeutic platforms aimed at treating the underlying causes of diseases rather than merely addressing their symptoms. The first platform, MYMD-1, is based on a small molecule in the clinical stage that regulates the immune system to control TNF-α, a driver of chronic inflammation, along with other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases characterized by acute or chronic inflammation.

The second platform, Supera-CBD, is a synthetic derivative of cannabidiol (CBD) designed to treat chronic pain, addiction, and epilepsy. This innovative drug aims to enhance the current CBD market, which includes both FDA-approved drugs and non-regulated CBD products.

These leadership changes and strategic appointments come as MyMD Pharmaceuticals continues to advance its clinical development programs, with a goal of extending healthy lifespan through innovative treatments. The company's commitment to progressing through mid-stage trials and beyond is underscored by the new expertise and leadership brought in by Dr. Glass and Mr. Friscia.